HCV replication inhibitors and its N- oxides, salt or stereoisomer with formula (I), wherein each Xu Line indicate optional double bond； X is N, CH, it is C when wherein X is with double bond； R1 is-OR7 ,-NH-SO2R8； R2 is H, and when X is C or CH, R2 can also be C1-6 alkyl； R3 is H, C1-6 alkyl, C1-6 alkoxy C 1-6 alkyl, C3-7 naphthenic base； R4 is aryl or Het； N is 3,4,5 or 6； R5 indicates halogenated, C1-6 alkyl, hydroxyl, C1-6 alkoxies, phenyl or Het； R6 indicates C1-6 alkoxies or dimethylamino； R7 is H, aryl, Het, the C1-6 alkyl optionally by the alkyl-substituted C3-7 naphthenic base of C1-6 or optionally replaced by C3-7 naphthenic base, aryl or Het； R8 is aryl, Het, the C1-6 alkyl optionally by the alkyl-substituted C3-7 naphthenic base of C1-6 or optionally replaced by C3-7 naphthenic base, aryl or Het； Aryl is the phenyl optionally replaced by 1,2 or 3 substituent group； Het is 5 or 6 yuan of saturations, part insatiable hunger and/or completely unsaturated containing the 1-4 heteroatomic heterocycles for being respectively selected from N, O and S, is optionally replaced by 1,2 or 3 substituent group； The method of pharmaceutical composition containing formula (I) and prepare compound (I). The HCV inhibitor for additionally providing formula (I) compound is combined with the bioavailable of ritonauir.具有式(I)的HCV複製抑制劑和其N-氧化物、鹽或立體異構體，其中每個虛綫表示任選的雙鍵；X是N、CH，其中X帶有雙鍵時它是C；R1是-OR7，-NH-SO2R8；R2是H，和當X是C或CH時，R2還可以是C1-6烷基；R3是H、C1-6烷基、C1-6烷氧基C1-6烷基、C3-7環烷基；R4是芳基或Het；n是3、4、5或6；R5表示鹵代、C1-6烷基、羥基、C1-6烷氧基、苯基或Het；R6表示C1-6烷氧基、或二甲基氨基；R7是H、芳基、Het、任選被C1-6烷基取代的C3-7環烷基或任選被C3-7環烷基、芳基或Het取代的C1-6烷基；R8是芳基、Het、任選被C1-6烷基取代的C3-7環烷基或任選被C3-7環烷基、芳基或Het取代的C1-6烷基；芳基是任選被1、2或3個取代基取代的苯基；Het是5或6元飽和、部分不飽和或完全不飽和的含有分別選自N、O和S的1-4個雜原子的雜環，任選被1、2或3個取代基取代；含有式(I)的藥物組合物和製備化合物(I)的方法。還提供了式(I)化合物的HCV抑制劑與利托那偉的生物可利用聯合。
